Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy

ÖZER F., Tokuc E., BAL ALBAYRAK M. G., AKPINAR G., KASAP M., KARABAŞ V. L.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.260, no.6, pp.1899-1906, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 260 Issue: 6
  • Publication Date: 2022
  • Doi Number: 10.1007/s00417-021-05515-3
  • Journal Name: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1899-1906
  • Keywords: Proliferative diabetic retinopathy, Intravitreal bevacizumab, Fibrosis, Intraocular hemorrhage, Tractional retinal detachment, TRACTIONAL FORCE GENERATION, MULLER CELLS, ANGIOGENIN, VEGF, MEDIATORS, FIBROSIS, AVASTIN
  • Kocaeli University Affiliated: Yes

Abstract

Purpose In diabetic retinopathy patients, intravitreal bevacizumab (IVB) injections are widely used to facilitate dissection of retinal fibrovascular membranes during surgery, reduce the rate of perioperative hemorrhage, and prevent recurrent neo-vascularization. Previous studies have shown that IVB may worsen fibrosis and thereby impair vision. The aim of this study was to determine which markers are associated with fibrosis.